Epi Data Slicer – Amyloidosis
Epi Data Slicer – Acute Myeloid Leukemia
The ulcerative colitis (UC) therapy market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer’s Xeljanz / Xeljanz XR) for moderate to severe…
Chemotherapy and hormonal therapy have been the mainstay treatments of advanced endometrial carcinoma, but treatment is becoming more directed, as a result of tumor analysis. Immune checkpoint…
Epi Data Slicer – Hodgkin's Lymphoma
Epi Data Slicer – Dry and Wet Age-Related Macular Degeneration
Epi Data Slicer – Alzheimer's Disease
Epi Data Slicer – Axial Spondyloarthritis
The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva),…
Since the approval of the first biosimilar in Europe more than a decade ago, the adoption of biosimilars has been increasing among all specialties. The FDA approved Sandoz’s Zarxio (filgrastim)…
CAR T-cell therapies, including Novartis’s Kymriah, Gilead / Kite’s Yescarta and Tecartus, and Celgene / Bristol Myers Squibb’s Breyanzi, have given new hope to patients with relapsed/…
Implementation of vaccination programs has had a revolutionary impact on global public health, not only leading to dramatic reductions in the incidence of infectious diseases but also reducing…
Clarivate Epidemiology’s coverage of uveitis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy,…
DRG Epidemiology's coverage of the HPV vaccine comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany…
Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…